Precision Psychiatry Platform
Biology-driven platform for predicting clinical response in neuropsychiatric conditions
Platform · OtherCompany source
Company profile
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company pioneering precision psychiatry through biology-driven medicine development. The company is disrupting the traditional trial-and-error approach to treating neuropsychiatric conditions by measuring brain biology to predict clinical response and match patients with treatments most likely to benefit them. Built on 15 years of field-leading neurobiology research, Alto develops novel medicines designed to target core brain processes in people suffering from neuropsychiatric conditions. The company's initial focus areas include major depressive disorder, bipolar depression, and schizophrenia. Alto's precision approach enables faster and more effective treatment outcomes by identifying patient subgroups based on neurobiological markers. The team leverages deep expertise in CNS drug development and commercialization to bring alternative treatment options to patients with mental health conditions.
Company description Alto Neuroscience official website
Mission. We develop biology-driven medicines for neuropsychiatric conditions so that patients can get better faster.
Primary marketMental Health & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Alto Neuroscience?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- bipolar depression
- major depressive disorder
- neuropsychiatric conditions
- schizophrenia
Who it serves
- Healthcare Providers
- Patients
- Pharma
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
Company milestones
Platform expansion
Clinical-stage pipeline development in major depressive disorder, bipolar depression, and schizophrenia
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Toward actionable biomarkers in psychiatry: a collaborative roadmap for precision clinical trials. An ACNP position paper.NPP - digital psychiatry and neuroscience · Sep 18, 2026
Towards precision psychiatry: initial foundations and future directions.Nature reviews. Drug discovery · Aug 24, 2026
Shared and specific associations of amygdala nuclei volumes with PTSD symptom domains and childhood trauma: An ENIGMA-PGC PTSD mega-analysis.Molecular psychiatry · Jul 2, 2026
Whole-brain mapping of TMS-induced discomfort with large-scale concurrent TMS-fMRI.bioRxiv : the preprint server for biology · May 6, 2026
Baseline Mismatch Negativity Amplitude Predicts Direction and Magnitude of Ketamine Effect in Healthy Volunteers: A Disordinal Effect.Biological psychiatry · Apr 15, 2026
Multimodal evidence for hippocampal engagement and modulation by functional connectivity-guided parietal TMS.Nature communications · Mar 8, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
faster patient improvement
precision matching of patients to treatments based on brain biology
clinical response prediction
identifying patients most likely to benefit from drug candidates
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Alto Neuroscience
Recent articles published on Alto Neuroscience's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Mental Health & Digital Therapeutics
Companies providing AI-powered mental health support, therapy platforms, mental wellness tracking, psychiatric care, digital therapeutics for mental health conditions, or AI-driven mental health screening and monitoring. Includes XR-based therapy, AI mental health screening infrastructure, and platforms supporting behavioral health for individuals and health systems.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.